Calliditas Q2 confirms continuing progress - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Calliditas Q2 confirms continuing progress - Redeye

Redeye highlights that Calliditas continue to progress with the lead candidate Nefecon and the company prepares for the US and European launch in 2022. Calliditas also confirm the key PDUFA date decision for Nefecon on 15th September, and the company is ready to initiate a well prepared US launch in late 2021. Financially the Q2 reflected the increased activity and did not include any significant surprises. Our Base case is likely to remain at SEK 280 per share, suggesting a significant upside potential from current levels.

Länk till analysen i sin helhet: https://www.redeye.se/research/818903/calliditas-q2-confirms-continuing-progress?utm_source=finwire&utm_medium=RSS

Nyheter om Calliditas Therapeutics

Läses av andra just nu

Om aktien Calliditas Therapeutics

Senaste nytt